Table 2. Phase III trials for thrombolytic treatment of acute ischemic stroke.

Compound	Mode of action	Study acronym	Time window	Outcome
rtPA	Thrombolysis	NIHSSG	3 Hours	Positive
rtPA	Thrombolysis	ECASS III	3–4.5 Hours	Positive
rtPA	Thrombolysis	ATLANTIS	3–6 Hours	Negative
Streptokinase	Thrombolysis	ASK	4 Hours	Negative
rtPA (alteplase)	Thrombolysis	ECASS I	6 Hours	Negative
rtPA (alteplase)	Thrombolysis	ECASS II	6 Hours	Negative
Ancrod	Thrombolysis	ASP II	6 Hours	Negative
Streptokinase	Thrombolysis	MAST	6 Hours	Negative
rPro-urokinase	Thrombolysis	PROACT II	6 Hours	Positive
Urokinase	Thrombolysis	PASS	6 Hours	Negative
dsPA (desmoteplase)	Thrombolysis	DIAS II	9 Hours	Negative

dsPA, desmodus rotundus salivary plasminogen activator; rtPA, recombinant tissue plasminogen activator.

Data from Stroke Trials Registry (http://www.strokecenter.org/trials).